Pages that link to "Q40354016"

The following pages link to The quest for an antibody-based HIV vaccine (Q40354016):

Displayed 44 items.

• Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV. (Q38688524) ‎ (← links)
• Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1. (Q40058876) ‎ (← links)
• Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer (Q40061438) ‎ (← links)
• Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. (Q41925820) ‎ (← links)
• Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era. (Q41928050) ‎ (← links)
• Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques (Q41933491) ‎ (← links)
• Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model (Q42377340) ‎ (← links)
• cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate (Q46067893) ‎ (← links)
• Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies. (Q46148243) ‎ (← links)
• The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection (Q47107303) ‎ (← links)
• Non-Neutralizing Antibodies Directed against HIV and Their Functions (Q47139556) ‎ (← links)
• FUNCTIONAL OPTIMIZATION OF BROADLY NEUTRALIZING HIV-1 ANTIBODY 10E8 BY PROMOTING MEMBRANE INTERACTIONS. (Q47547492) ‎ (← links)
• The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. (Q52581587) ‎ (← links)
• Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. (Q52673965) ‎ (← links)
• Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys. (Q55411829) ‎ (← links)
• RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses (Q57025317) ‎ (← links)
• Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation (Q57295484) ‎ (← links)
• HIV-1 vaccine design through minimizing envelope metastability (Q59339672) ‎ (← links)
• Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost (Q59351003) ‎ (← links)
• Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs (Q59352769) ‎ (← links)
• The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256 (Q60301724) ‎ (← links)
• Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions (Q60917642) ‎ (← links)
• Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide (Q61795909) ‎ (← links)
• Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence (Q64093092) ‎ (← links)
• The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template (Q64281085) ‎ (← links)
• Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity. (Q64982392) ‎ (← links)
• Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses (Q88582157) ‎ (← links)
• The expanding role of mass spectrometry in the field of vaccine development (Q88935087) ‎ (← links)
• Immune checkpoint modulation enhances HIV-1 antibody induction (Q89790825) ‎ (← links)
• Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles (Q90082642) ‎ (← links)
• Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies (Q90135569) ‎ (← links)
• Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy (Q90176802) ‎ (← links)
• T cell-based strategies for HIV-1 vaccines (Q90479100) ‎ (← links)
• Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models (Q90629708) ‎ (← links)
• Engineering immunity for next generation HIV vaccines: The intersection of bioengineering and immunology (Q91413247) ‎ (← links)
• Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin (Q92093979) ‎ (← links)
• Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses (Q92147755) ‎ (← links)
• Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination (Q92264819) ‎ (← links)
• Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1 (Q92327047) ‎ (← links)
• The potential of plant systems to break the HIV-TB link (Q92600927) ‎ (← links)
• Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms (Q93150667) ‎ (← links)
• HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies (Q94458567) ‎ (← links)
• Pharmaceutical Approaches to HIV Treatment and Prevention (Q98292337) ‎ (← links)
• RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines (Q98611597) ‎ (← links)